Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review
暂无分享,去创建一个
[1] R. Fisher,et al. Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial , 2011, Clinical Cancer Research.
[2] P. Kienle,et al. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. , 2011, International journal of radiation oncology, biology, physics.
[3] David D. Smith,et al. Identification of a Biomarker Profile Associated With Resistance to Neoadjuvant Chemoradiation Therapy in Rectal Cancer , 2011, Annals of surgery.
[4] Hein Putter,et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.
[5] R. Fisher,et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Sydes,et al. Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. , 2010, International journal of radiation oncology, biology, physics.
[7] K. Ang,et al. Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.
[8] J. Ragoussis,et al. hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer , 2010, Cancer.
[9] T. Nielsen,et al. Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Paik,et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Oza,et al. Phase 1 Study of Tirapazamine in Combination With Radiation and Weekly Cisplatin in Patients With Locally Advanced Cervical Cancer , 2010, International Journal of Gynecologic Cancer.
[12] Howard Colman,et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. , 2010, Neuro-oncology.
[13] G. Reifenberger,et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Reifenberger,et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] H. Hollema,et al. Expression of Epidermal Growth Factor Receptor (EGFR) and Activated EGFR Predict Poor Response to (Chemo)radiation and Survival in Cervical Cancer , 2009, Clinical Cancer Research.
[16] I. Nagtegaal,et al. PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients , 2009, Clinical Cancer Research.
[17] A. Iafrate,et al. MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA , 2009, Neurology.
[18] M. Seong,et al. Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Andrew J Vickers,et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Hammond,et al. The Importance of Protein Kinase A in Prostate Cancer: Relationship to Patient Outcome in Radiation Therapy Oncology Group Trial 92-02 , 2009, Clinical Cancer Research.
[21] Kyounghwa Bae,et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Roach,et al. Predictive models in external beam radiotherapy for clinically localized prostate cancer , 2009, Cancer.
[23] M. J. van de Vijver,et al. Local Recurrence after Breast-Conserving Therapy in Relation to Gene Expression Patterns in a Large Series of Patients , 2009, Clinical Cancer Research.
[24] J. Weidhaas,et al. Changes in Gene Expression Predicting Local Control in Cervical Cancer: Results from Radiation Therapy Oncology Group 0128 , 2009, Clinical Cancer Research.
[25] E. Perez,et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Jens Overgaard,et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Caterina Giannini,et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] R. Jenkins,et al. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. , 2008, Cancer journal.
[29] D. Grignon,et al. Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10. , 2008, International journal of radiation oncology, biology, physics.
[30] Lars Påhlman,et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] E. Domany,et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D. Grignon,et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Barbara L. Smith,et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] A. Brandes,et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] W. Westra,et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. , 2008, Journal of the National Cancer Institute.
[36] D. Grignon,et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] A. Iafrate,et al. Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers , 2008, Journal of neuropathology and experimental neurology.
[38] A. Ardizzoni,et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy , 2007, British Journal of Cancer.
[39] D. Grignon,et al. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. , 2007, International journal of radiation oncology, biology, physics.
[40] E. Taioli,et al. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta‐analysis , 2007, International journal of cancer.
[41] D. Grignon,et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. , 2007, The Lancet. Oncology.
[42] H. Bartelink,et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] M. Kattan,et al. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. , 2007, Urology.
[44] Christopher U. Jones,et al. Microvessel Density ≥60 Does Not Predict for Outcome After Radiation Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma: Results of a Correlative Study From the Radiation Therapy Oncology Group (RTOG) 90-03 Trial , 2007, American journal of clinical oncology.
[45] Laurence Collette,et al. Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial , 2007 .
[46] D. Grignon,et al. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] H. Sandler,et al. Bcl-2 and Bax Expression Predict Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy on Radiation Therapy Oncology Group Protocol 92-02 , 2007, Clinical Cancer Research.
[48] C. Sotiriou,et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.
[49] M. Agostini,et al. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation , 2006, Pharmacogenetics and genomics.
[50] C. Sempoux,et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[51] I. Brandslund,et al. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. , 2006, International journal of radiation oncology, biology, physics.
[52] K. Song,et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. , 2006, International journal of radiation oncology, biology, physics.
[53] Christine H Chung,et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Walter Curran,et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] O. Olopade,et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] Yoko Yamamoto,et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. , 2006, Cancer research.
[57] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[58] R. Collins,et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[59] Min Zhang,et al. Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610. , 2005, International journal of radiation oncology, biology, physics.
[60] J. Overgaard,et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. , 2005, The Lancet. Oncology.
[61] D. Brizel,et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[62] K. Trott,et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] W. Landuyt,et al. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy , 2005, BMC Cancer.
[64] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[65] R. Simon,et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[67] Howard Y. Chang,et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[68] L. Cerezo,et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[69] D. Grignon,et al. Ki-67 Staining Index Predicts Distant Metastasis and Survival in Locally Advanced Prostate Cancer Treated With Radiotherapy , 2004, Clinical Cancer Research.
[70] M. Hammond,et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] J. Lee,et al. Synchronous Coexpression of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in Carcinomas of the Uterine Cervix , 2004, Clinical Cancer Research.
[72] Tak-Hong Cheung,et al. Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[73] Kenji Tada,et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.
[74] P. Okunieff,et al. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] L. Mazzucchelli,et al. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. , 2003, International journal of radiation oncology, biology, physics.
[76] R. Pötter,et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[77] Johan Bussink,et al. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[78] S. Clarke,et al. p53, Deleted in Colorectal Cancer Gene, and Thymidylate Synthase as Predictors of Histopathologic Response and Survival in Low, Locally Advanced Rectal Cancer Treated With Preoperative Adjuvant Therapy , 2003, Diseases of the colon and rectum.
[79] M. Marton,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[80] Ruth Katz,et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.
[81] R. Pötter,et al. Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer , 2002, International journal of cancer.
[82] Y. Harima,et al. Human papilloma virus (HPV) DNA associated with prognosis of cervical cancer after radiotherapy. , 2002, International journal of radiation oncology, biology, physics.
[83] G Starkschall,et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] G S Bauman,et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. , 2000, International journal of radiation oncology, biology, physics.
[85] J. Logue,et al. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix , 2000, British Journal of Cancer.
[86] A. Hanlon,et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. , 2000, International journal of radiation oncology, biology, physics.
[87] J. Poen,et al. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. , 1999, Cancer research.
[88] M. J. van de Vijver,et al. Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. , 1998, International journal of radiation oncology, biology, physics.
[89] M. Dewhirst,et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.
[90] D. Grignon,et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. , 1997, Journal of the National Cancer Institute.
[91] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[92] G. Paludetti,et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. , 1996, British Journal of Cancer.
[93] J. Grandis,et al. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. , 1993, Cancer research.
[94] R. Heald,et al. RECURRENCE AND SURVIVAL AFTER TOTAL MESORECTAL EXCISION FOR RECTAL CANCER , 1986, The Lancet.
[95] Cyrus Chargari,et al. Controversies and challenges regarding the impact of radiation therapy on survival. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[96] C. Grau,et al. The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy--results from the randomized DAHANCA 5 study. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[97] Jordi Giralt,et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.
[98] D. Alberts,et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. , 2010, The Cochrane database of systematic reviews.
[99] S. Bettelli,et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[100] F. Ducray,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[101] Lei Dong,et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.
[102] L. Solin,et al. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] R. Livingston,et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] P. Etienne,et al. Supplemental Table S2 , 2012 .
[105] H. Ishikawa,et al. The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with Stage IIIB cervical carcinoma treated with radiation therapy alone , 2001, Cancer.
[106] S. Lundgren,et al. Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. , 1996, Acta oncologica.
[107] HighWire Press,et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. , 1983 .